EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

EpiVax-Guilhem

More Like This

PR Newswire associated0

EpiVax Drives Immunogenicity Innovation in 2024: Year in Review

PR Newswire associated0

Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

PR Newswire associated0

EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs

New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented

PR Newswire associated0

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

ACCESSWIRE logo

BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD